InVivoMAb Anti-Human/Mouse VSIG4/CRIg Antibody (Iv0141)

Catalog #: VHK26801 Specific References (0) DATASHEET

Bioactivity for InVivoMAb Anti-Human/Mouse VSIG4/CRIg Antibody (Iv0141) ?>

Neutralization for InVivoMAb Anti-Human/Mouse VSIG4/CRIg Antibody (Iv0141) ?>

Host species: Mouse

Isotype: VHH-mFc (IgG1)

Applications: ELISA, Neutralization

Accession: Q9Y279

Overview

Catalog No.

VHK26801

Species reactivity

Human, Mouse

Host species

Mouse

Isotype

VHH-mFc (IgG1)

Clonality

Monoclonal

Applications

ELISA, Neutralization

Target

Protein Z39Ig, CRIg, V-set and immunoglobulin domain-containing protein 4, VSIG4, Z39IG

Concentration

3.63 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9Y279

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0141

Note

For research use only. Not suitable for clinical or therapeutic use.

Data Image

SEC-HPLC

The purity of this product is >95% as determined by SEC-HPLC.
Bioactivity

(I) Schematic diagram for anti-VSIG4 and anti-PD-1 combination therapy in HCC somatic mouse model. (J) Relative luciferase fold change curves in HCC somatic mouse model after treating with anti-VSIG4, anti-PD-1, or combination therapy were monitored by in vivo biofluorescence (n = 8 per group). (K) Kaplan-Meier survival curves of HCC-bearing mice after treating with anti-VSIG4, anti-PD-1, or combination therapy (n = 8 per group). (L and M) Representative image of Hepa 1-6 orthotopic mice model after treating with anti-VSIG4, anti-PD-1, or combination therapy (L). Visible tumors were dissected and weighted, mean ± SD (M). Treatment was initiated at 7 days after the inoculated with Hepa 1-6 cells and was given every 3 days. (N and O) Representative immunofluorescent images for TUNEL+/CK+ apoptotic orthotopic Hepa 1-6 cells after treating with anti-VSIG4, anti-PD-1 or combination therapy. Scale bars, 50 μm. Quantification, right; mean ± SD. (C, F, and H) p value by Student's t test; (J, M, and O) p value by one-way ANOVA. A p value of less than 0.05 indicates a statistical difference.
Data sourced from citation (PMID: 40339578)
Neutralization

Figure S7. VSIG4 inhibit T cell activation, related to Figure 4. (E) Tumor growth curves of CT26 tumors in BALB/c mice (n = 6 mice). At day 7 post-tumor inoculation, mice were treated with vehicle, anti-PD-1 (2.5 mg/kg, i.p., twice a week), anti-VSIG4 (2.5 mg/kg, i.p., twice a week), TP-18 (50 mg/kg, p.o., daily), the combination of anti-VSIG4 and TP-18, anti-PD-1 and anti-VSIG4, anti-PD-1 and TP-18, or the triple combination of anti-PD-1, anti-VSIG4 and TP-18. Mean ± SEM. One-way ANOVA with Tukey's multiple comparison test. ***p < 0.001.
Data sourced from citation (PMID: 42213779)

References

Datasheet

Document Download

InVivoMAb Anti-Human/Mouse VSIG4/CRIg Antibody (Iv0141).pdf

$ 280

Product specifications

100 μg 280 1 mg 1120 5 mg 3360

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here